ANEBULO PHARMACEUTICALS INC (ANEB) Forecast, Price Target & Analyst Ratings

NASDAQ:ANEB • US0345691036

Current stock price

0.36 USD
-0.07 (-16.49%)
At close:
0.382 USD
+0.02 (+6.11%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ANEBULO PHARMACEUTICALS INC (ANEB).

Forecast Snapshot

Consensus Price Target

Price Target
$8.16
+ 2,166.67% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q3 / 2026
EPS Estimate
-$0.14
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
43.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.16
Upside
+ 2,166.67%
From current price of $0.36 to mean target of $8.16, Based on 6 analyst forecasts
Low
$8.08
Median
$8.16
High
$8.40

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

6 Wall Street analysts provided a forecast for the next 12 months for ANEB. The average price target is 8.16 USD. This implies a price increase of 2166.67% is expected in the next year compared to the current price of 0.36.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ANEB Current Analyst RatingANEB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

ANEB Historical Analyst RatingsANEB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
43.33%
ANEB was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about ANEB.
In the previous month the buy percentage consensus was at a similar level.
ANEB was analyzed by 6 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-07-23Maxim GroupDowngrade Buy -> Hold
2025-05-15Maxim GroupMaintains Buy -> Buy
2024-11-19BenchmarkReiterate Speculative Buy -> Speculative Buy
2024-10-01BenchmarkReiterate Speculative Buy -> Speculative Buy
2023-10-03BenchmarkReiterate Speculative Buy -> Speculative Buy
2023-09-25HC Wainwright & Co.Reiterate Buy -> Buy
2023-09-21Maxim GroupInitiate Buy
2023-09-18HC Wainwright & Co.Initiate Buy
2023-05-18BenchmarkReiterate Speculative Buy -> Speculative Buy
2023-02-14BenchmarkMaintains Speculative Buy
2022-07-27Ladenburg ThalmannInitiate Buy
2021-05-25BenchmarkInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q3 / 2026
EPS Estimate
-$0.14
Revenue Estimate
N/A
Revenue Q2Q
N/A
EPS Q2Q
-257.00%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

ANEB is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is null USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ANEB revenue by date.ANEB revenue by date.
N/AN/AN/A
-100.00%		N/AN/AN/AN/A
159.56%		N/A
62.22%
EBITDA
YoY % growth
ANEB ebitda by date.ANEB ebitda by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
ANEB ebit by date.ANEB ebit by date.
-170K-3.61M
-2,023.53%		-6.83M
-89.20%		-11.78M
-72.47%		-8.309M
29.47%		-9.224M
-11.01%		N/A
-60.98%		N/A
-20.00%		N/A
-15.68%		N/A
-15.89%		N/A
-20.73%		N/A
89.25%		N/A
1,429.00%		N/A
115.12%
Operating Margin
ANEB operating margin by date.ANEB operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
ANEB eps by date.ANEB eps by date.
N/AN/AN/A
56.45%		-0.47
-70.66%		-0.32
31.91%		-0.26
18.75%		N/A
-88.31%		N/A
4.17%		N/A
-6.52%		N/A
430.61%		N/A
62.35%		N/A
35.36%		N/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.14
-257.00%		-0.10
-104.00%		-0.11
-124.40%		-0.11
-124.40%		-0.12
14.29%		-0.13
-30.00%
Revenue
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-3.861M
-104.02%		-4.009M
-71.98%		-4.098M
-81.32%		-4.276M
-63.21%		-4.633M
-20.00%		-4.81M
-20.00%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ANEB Yearly Revenue VS EstimatesANEB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 2032 2033 50M 100M
ANEB Yearly EPS VS EstimatesANEB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-24.34%
EPS Next 5 Year
65.24%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ANEBULO PHARMACEUTICALS INC / ANEB Forecast FAQ

What is the average price target for ANEBULO PHARMACEUTICALS INC (ANEB) stock?

6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 2166.67% is expected in the next year compared to the current price of 0.36.

Can you provide the upcoming earnings date for ANEBULO PHARMACEUTICALS INC?

ANEBULO PHARMACEUTICALS INC (ANEB) will report earnings on 2026-05-11.

What is the consensus rating for ANEB stock?

The consensus rating for ANEBULO PHARMACEUTICALS INC (ANEB) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.